Treatment
Cyclophosphamide clinical trials
We’re tracking 524 recruiting studies that include Cyclophosphamide, each written for real people, not researchers, below.
Recruiting studies
- NCT07570563RecruitingPhase 1/Phase 2
T Cell Immunotherapy for Advanced Cancers
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07588360Recruiting
Stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
Fuzhou, FujianAges 14–60 - NCT07589543RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Ovarian Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight ovarian cancer that has returned or stopped responding to standard treatments. The therapy uses cells from your own body that have been modified in the lab to recognize and attack cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT07598955RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Relapsed Thymoma or Thymic Carcinoma
This trial tests a new type of immune cell therapy called CAR-NK cells, which are designed to fight thymoma or thymic carcinoma (cancers of the thymus gland) that has come back or stopped responding to prior treatments. The goal is to see if these engineered cells can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT07608978RecruitingPhase 2
New drug combination for untreated aggressive lymphoma
This study tests a combination of five drugs (including a targeted therapy called polatuzumab vedotin) for patients with a specific type of aggressive lymphoma (DLBCL) that has never been treated before. The goal is to see if this combination works better and is safe for certain subtypes of this cancer.
Nanjing, JiangsuAges 18 years+ - NCT07613723RecruitingPhase 1
Testing ZI-MA4-1 immunotherapy for advanced solid cancers
This early-stage trial tests a new type of immunotherapy called ZI-MA4-1 in patients with advanced cancers (ovarian, lung, synovial sarcoma, or head and neck) that have stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells that have a specific protein called MAGE-A4.
LondonAges 18–75 - NCT07614061RecruitingPhase 1
Cell therapy for advanced bile duct cancer
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
ShanghaiAges 18 years+ - NCT07617753RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Recurrent Ovarian Cancer
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07627698RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Melanoma
This trial tests engineered immune cells (CAR-NK cells) designed to target two markers found on melanoma cells. The goal is to help patients with melanoma that has spread or cannot be surgically removed and has not responded to or is unsuitable for standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+ - NCT07641036RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Biliary Tract Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target cancer cells in advanced biliary tract cancers—including bile duct and gallbladder cancers. The cells are engineered to recognize and attack cancer cells that have specific markers (HER2 and CEA), and this approach may help patients whose cancer has progressed after standard chemotherapy.
Shenzhen, GuangdongAges 18 years+ - NCT07652879RecruitingPhase 2
KCD drug combination for newly diagnosed POEMS syndrome
This trial tests a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people newly diagnosed with POEMS syndrome. It aims to see how well this treatment helps control the disease and its symptoms.
ShanghaiAges 18–75 - NCT07668557RecruitingPhase 1
CLL1-CD33 CAR-T cells for relapsed or refractory acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Nanchang, JiangxiAges 18–70 - NCT07258680Enrolling by invitationPhase 3
Testing brentuximab and etoposide for T-cell lymphoma
This trial tests whether adding the drugs brentuximab and etoposide to standard chemotherapy improves treatment for people newly diagnosed with T-cell lymphoma. It aims to find a more effective first treatment option.
Ages 18–70 - NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT07038447Enrolling by invitationPhase 1
KITE-363 for refractory autoimmune diseases
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06518668Enrolling by invitationPhase 1
NKX019 cell therapy for lupus
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
New York, New YorkAges 18–65 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80
Common questions
- Are there clinical trials studying Cyclophosphamide?
- Yes. Clin2 currently lists 524 recruiting studies that include Cyclophosphamide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cyclophosphamide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cyclophosphamide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cyclophosphamide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.